Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 14/20 | 0.33 |
| ▸ | CDK8 | P49336 | 14/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479513 | 0.83 | — | — | |
| SCHEMBL769784 | 0.79 | CRBN (0.32) | — | |
| SCHEMBL1429855 | 0.78 | OTUD7B (0.46) | OTUD7BCCNCCDK8IDO1JAK1 | |
| SCHEMBL21584978 | 0.78 | — | — | |
| SCHEMBL324340 | 0.78 | OTUD7B (0.46) | OTUD7BCCNCCDK8IDO1JAK1 | |
| SCHEMBL3119994 | 0.78 | OTUD7B (0.46) | OTUD7BCCNCCDK8IDO1JAK1 | |
| Hydrochloric Acid SCHEMBL2637685 | 0.76 | OTUD7B (0.44) | OTUD7BCCNCCDK8IDO1JAK1 | |
| Hydrochloric Acid SCHEMBL30159811 | 0.76 | OTUD7B (0.44) | OTUD7BCCNCCDK8IDO1JAK1 | |
| Hydrochloric Acid SCHEMBL325043 | 0.76 | OTUD7B (0.44) | OTUD7BCCNCCDK8IDO1JAK1 | |
| SCHEMBL4829 | 0.76 | OTUD7B (0.44) | OTUD7BCCNCCDK8IDO1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-06-15 | — | — | US | claimed |
| EP-3122739-B1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2019-01-16 | — | — | EP | claimed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | claimed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | claimed |
| EP-3122739-A1 | PYRIDYL PIPERIDINES | Merck Patent GmbH (DE) | 2017-02-01 | — | — | EP | claimed |
| WO-2015144290-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | WO | claimed |
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | claimed |
| JP-4726238-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| WO-2008100564-A1 | LTA4H MODULATORS AND USES THEROF | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | claimed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | claimed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | claimed |
| WO-2006105304-A2 | PHENYL AND PYRIDYL LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | US | claimed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | claimed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | LRRK2, BRSK2, MAPKAPK2 | OTUD7B 3045/4885CCNC 3618/4885CDK8 1484/4885 |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | OTUD7B 1995/4885CCNC 3333/4885CDK8 3671/4885 |
| US-20060223792-A1 | Phenyl and pyridyl LTA4H modulators | LTA4H, LTB4R, LTC4S | OTUD7B 3667/4885CCNC 3687/4885CDK8 943/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | OTUD7B 1603/4885CCNC 3373/4885CDK8 2114/4885 |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | WNT1, CTNNB1, WNT3 | OTUD7B 1846/4885CCNC 51/4885CDK8 275/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | OTUD7B 2580/4885CCNC 3855/4885CDK8 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.